Related Experiment Videos
Insights
Statins are key cardiovascular drugs, but caution is advised in heart failure. Niacin offers an alternative, while ACE inhibitors and calcium channel blockers have specific benefits and risks.
Area of Science:
- Cardiovascular pharmacotherapy
- Pharmacological interventions for cardiovascular diseases
Context:
- Current cardiovascular pharmacotherapy emphasizes statins (HMG-CoA-reductase inhibitors) for their lipid-lowering and antiatherogenic effects.
- Statins show potential benefits in senile dementia, stroke, osteoporosis, and reducing ventricular arrhythmias.
- Chronic heart failure management requires caution with statins due to potential links between low cholesterol and impaired survival.
Purpose:
- To review current trends and considerations in cardiovascular pharmacotherapy.
- To highlight the roles of various drug classes and emerging treatments in cardiovascular disease management.
Summary:
- Statins are central to cardiovascular pharmacotherapy, offering antihyperlipidaemic and antiatherogenic benefits, with potential roles in neurological and bone health.
- Niacin is presented as an alternative to statins and fibrates.
- ACE inhibitors demonstrate benefit post-myocardial infarction, though long-term efficacy is comparable to other agents.
- Calcium channel antagonists may increase cardiovascular complications but reduce stroke risk in high-risk individuals.
- Biventricular pacing and artificial ventricle implantation represent advanced therapies for severe heart failure.
- Cardiospecific troponin I and T-cadherin are discussed as diagnostic markers and cellular components.
- Etamoxir shows promise as a novel heart failure treatment.
- Nitric oxide use post-congenital heart surgery mitigates pulmonary hypertensive crises.
Impact:
- Provides an overview of established and emerging cardiovascular pharmacotherapies.
- Informs clinical decision-making regarding statin use in specific conditions like heart failure.
- Highlights the evolving landscape of cardiovascular disease treatment and diagnostics.
Abstract:
In cardiovascular pharmacotherapy, the main focus is now on statins (HMG-CoA-reductase inhibitors) because of their antihyperlipidaemic and antiatherogenic effect. They are suggested to be beneficial also in senile dementia, stroke and osteoporosis and they can reduce incidence of ventricular arrhythmias in patients with cardioverter-defibrillator. In chronic heart failure, statins should be used with caution since reduced cholesterol levels relate to impaired survival. As an alternative to statins and fibrates, niacin therapy may be considered. ACE inhibitors are of proven benefit for patients with left ventricular dysfunction after acute myocardial infarction; however, in long-term treatment, their protective activity is not superior to that of beta-blockers, diuretics and clonidine. Ca-channel antagonists slightly increase the incidence of cardiovascular complications but reduce the incidence of stroke in high-risk patients. Biventricular pacing has been used with success in patients with severe heart failure and conduction disturbances, and the first permanent artificial ventricle was implanted to a patient with irreversible terminal heart failure in summer 2000. Cardiospecific troponin I may be an uninvasive marker of a procoagulant status indicating e.g. graft failure after cardiac transplantation; T-cadherin belongs to the cell-adhesion molecules and has a role in maintenance of cellular contacts which are critical for the vessel wall architecture. Etamoxir, originally developed for the treatment of diabetes II, has recently been shown to be a potential novel drug for heart failure. Routine use of nitric oxide after congenital heart surgery lessens the risk of pulmonary hypertensive crises.